The dystrophin gene

Dystrophin is a large protein that acts as a shock-absorber inside muscle fibres, protecting them from damage during contraction. Without it, muscle fibres tear repeatedly, trigger inflammation, and are gradually replaced by fat and fibrotic tissue.

The dystrophin gene is the largest gene in the human genome — which makes it particularly prone to mutations. Most mutations are deletions (a segment of genetic code is missing), though duplications and point mutations also occur.

How it's inherited

DMD and BMD are X-linked recessive conditions. The dystrophin gene sits on the X chromosome. Males have one X chromosome — if it carries the mutation, they have DMD or BMD. Females have two X chromosomes — usually one working copy means they're carriers rather than affected (though an estimated 10–40% of carriers develop cardiac involvement).

What BMD looks like

BMD presentation is highly variable. Some men have significant weakness from childhood; others have minimal symptoms until their 20s, 30s, or even 40s. Calf enlargement (pseudohypertrophy), exercise intolerance, and muscle cramps are common early features.

BMD cardiac monitoring schedule

Muscles in BMD

Physiotherapy and avoiding prolonged immobility help preserve function. Steroids are used less often in BMD than in DMD — doctors don't yet agree on how much they help. Discuss with your neurologist: some men with BMD benefit, others don't need them.

Classic early signs in DMD (typically ages 2–5)

• Calf pseudohypertrophy — enlarged, firm calves (fat and fibrotic tissue replacing muscle)
• Delayed motor milestones — walking after 18 months, not running, difficulty with stairs
• Gowers' sign — getting up from the floor by "walking hands up legs" due to proximal weakness
• Toe-walking — tight Achilles tendons from early on
• Frequent falls — more than peers of the same age
• Waddling gait — hip girdle weakness
• Elevated CK on routine blood test — CK is often 10–100× normal in DMD, even before symptoms

What to do if you suspect DMD or BMD

1. Serum CK level — a simple blood test. Extremely elevated (>1000 U/L, often >10,000 in DMD) strongly suggests dystrophinopathy.
2. Refer to a paediatric neurologist — preferably one with neuromuscular experience. AIIMS Delhi, NIMHANS Bangalore, CMC Vellore, and large teaching hospitals have neuromuscular clinics.
3. Genetic testing: MLPA — confirms the diagnosis and identifies the specific mutation. This is the single most important test.
4. Do not wait for a muscle biopsy — genetic testing has replaced muscle biopsy as first-line in most cases. Biopsy is now reserved for atypical presentations.

What steroids do in DMD

• Extend walking by 2–5 years
• Substantially reduce scoliosis risk
• Preserve upper limb function longer
• Reduce the risk of needing nocturnal ventilation
• May help cardiac function

Which steroid? Deflazacort vs prednisone

When to start

International guidelines recommend starting when motor function plateaus — typically age 4–6, once the child is walking well. Starting earlier (before age 4) is not standard; starting after loss of walking has less benefit. The correct timing should be discussed with a paediatric neurologist.

Dosing regimens

Three main approaches are used: daily dosing (most studied), 10 days on / 10 days off, and weekend-only dosing. Weekend or intermittent dosing is sometimes chosen to reduce side-effect burden while maintaining much of the benefit. Your neurologist will guide this.

Managing side effects

• Weight gain — dietary management; low-salt, controlled-carbohydrate diet; deflazacort causes less weight gain
• Bone density — calcium and vitamin D supplementation essential; annual DEXA scan if available
• Growth — mild height reduction; monitor
• Behaviour — mood changes, hyperactivity; often improves with lower doses or dosing adjustment
• Eye pressure — annual ophthalmology review for glaucoma/cataracts
• Blood pressure — monitor at each visit

Why the heart is affected

The heart is a muscle, and dystrophin is needed in the heart as much as in the legs. In DMD, cardiac muscle is damaged by the same process as skeletal muscle. By age 18, virtually all young men with DMD have some cardiac involvement. The heart can weaken silently — there are often no symptoms until function is already significantly reduced.

The key cardiac intervention: ACE inhibitors from age 10

Enalapril and lisinopril (ACE inhibitors) started at age 10 — even before any echo abnormality — have been shown to delay the onset and slow the progression of cardiomyopathy. This is an inexpensive intervention that remains under-used in India.

Cardiac monitoring schedule for DMD

Signs of cardiac problems to watch for

What happens to breathing in DMD

The diaphragm and intercostal muscles weaken over time. This most commonly manifests as nighttime hypoventilation first — the body doesn't breathe deeply enough during sleep. Symptoms can be subtle: morning headaches, tiredness on waking, restless sleep, more frequent respiratory infections.

Respiratory monitoring schedule

Nocturnal BiPAP

BiPAP (bi-level positive airway pressure) delivered through a nasal or face mask during sleep is the standard intervention when nighttime breathing is compromised. It supports breathing rather than taking it over completely. Most young men adapt well and sleep better once started.

Vaccinations

Children with DMD are at high risk from respiratory infections. Ensure influenza vaccination annually and pneumococcal vaccination per standard schedule. These are available at government health centres.

Key principles

• Avoid prolonged immobility — even a few weeks of bedrest can accelerate muscle loss
• No aggressive strengthening — high-intensity resistance exercise can damage dystrophic muscle
• Stretching daily — prevents contractures of ankles, knees, hips, and arms
• Hydrotherapy / swimming — low-impact, excellent for maintaining function
• Positioning and seating — correct wheelchair seating prevents scoliosis and pressure injury

Stage-specific physiotherapy

Exon-skipping therapies

Exon-skipping drugs (eteplirsen, golodirsen, viltolarsen, casimersen) work for specific deletion mutations by restoring partial dystrophin production. They are FDA-approved and available in the USA. In India, they are not commercially approved. Cost in the USA: roughly ₹2.5 crore to over ₹10 crore per year, since dosing (and therefore cost) scales with the patient's body weight.

Elevidys (delandistrogene moxeparvovec) — gene therapy

Elevidys is a gene therapy delivering a micro-dystrophin construct. FDA-approved in the USA. Cost: approximately USD 3.2 million (one dose). Not available in India (it launched commercially in Japan in February 2026, its first major Asian market). Important: On 14 November 2025, the FDA added a boxed warning for serious/fatal liver injury and restricted the approved use to ambulatory patients aged 4 and up — the non-ambulatory indication was withdrawn. This should be discussed carefully with a neuromuscular specialist before considering overseas access.

Givinostat

A histone deacetylase inhibitor (brand name Duvyzat) approved by the FDA in March 2024 for DMD. Not currently available in India.

What to watch for

Deramiocel, a cell therapy for DMD-related cardiomyopathy, has an FDA decision expected sometime in 2026 — not yet approved or available anywhere, but worth watching.

What this means practically

Steroids (deflazacort or prednisolone) remain the most important treatment you can access and afford in India right now. Exon-skipping and gene therapies may become available in India in coming years — keeping the genetic test result is important for future eligibility.

How inheritance works

• The dystrophin gene is on the X chromosome
• Males (XY): one X — if it carries the mutation, they have DMD or BMD
• Females (XX): two X chromosomes — usually one working copy protects them (carriers)
• Carrier mother: 50% chance each son has DMD/BMD; 50% chance each daughter is a carrier
• Affected father: ALL daughters are carriers (100% — not 50%); no sons are affected
• ~1/3 of cases are de novo (new) mutations — no prior family history. Carrier testing of the mother is still important.

Carrier testing and family planning options in India

What to do in the early years

• Confirm the genetic diagnosis — exact mutation type and exon coordinates via MLPA
• Establish with a paediatric neurologist — preferably with neuromuscular experience
• Baseline cardiac assessment — ECG + echo at diagnosis
• Begin physiotherapy — stretching, swimming, appropriate play activities
• Speech and swallowing assessment — some children have subtle swallowing difficulties
• Developmental and cognitive assessment — learning differences occur in ~30% of boys with DMD, independent of physical ability
• Discuss steroid timing — with your neurologist; typically started age 4–6 at motor plateau

Medical priorities at this stage

• Steroids optimised (deflazacort or prednisolone dose, regimen)
• Calcium + vitamin D supplementation ongoing
• Annual cardiac review; ACE inhibitor started by age 10
• Annual spirometry from age 6
• Annual ophthalmology (steroid side effects)
• Orthopaedic review — ankle contractures, early scoliosis watch
• Physiotherapy: daily ankle stretches, swimming, no high-impact sports

School inclusion rights in India

Under the Right to Education Act (RTE) and the RPwD Act 2016, children with DMD have the right to inclusive education in neighbourhood schools with reasonable accommodations. Muscular Dystrophy is explicitly listed in the RPwD Act.

Managing the transition to a wheelchair

• Start wheelchair skills training and seating assessment before walking becomes unsafe
• Powered wheelchairs offer greater independence — assess eligibility
• Upper limb exercises become the focus of physiotherapy
• Respiratory: annual spirometry; FVC trending down signals need for sleep study
• Scoliosis surveillance: spinal X-rays; surgical referral if >20–30 degrees and still growing

Emotional support

The transition to a wheelchair is often described by young men with DMD as emotionally harder than the physical change. Peer connection — with other young people with DMD — helps, and many families say it makes a real difference. PPMD India (ppmdindia.org) has peer support resources. It helps to bring in psychological support early, rather than waiting until things reach a crisis.

Medical priorities in adulthood

• Annual cardiac review — echocardiogram + ECG; optimize heart failure therapy
• Respiratory: nocturnal BiPAP if indicated; cough assist device; annual pulmonology review
• Scoliosis management — surgical correction if appropriate
• Pain management — musculoskeletal pain is common and underappreciated
• Mental health — depression and anxiety are common; seek support proactively
• Transition from paediatric to adult services — plan this actively, not in crisis

Higher education and employment

Many young men with DMD pursue higher education and careers that do not require physical strength. Under the RPwD Act 2016, 5% of seats in higher education must be reserved for persons with benchmark disabilities. Employment protections apply. The UDID card is the basis for accessing these rights.

Step 1: Get the UDID card

The Unique Disability ID (UDID) card is your proof of disability and the basis for accessing all rights and schemes. Apply online at swavlambancard.gov.in or at your district CMO/disability office. Assessment is done by a government medical board. Disability certificate: apply using Form-IV under RPwD Act rules (the certificate itself is then issued on a separate form) — required for most benefits.

Education rights

• Right to Education Act: inclusive education in neighbourhood schools
• Reasonable accommodations: accessible classroom, extra time, scribe, exemption from PE
• 5% reservation in higher education institutions (including central and state universities)
• Scholarship schemes under National Scholarship Portal (scholarships.gov.in)

Employment rights

• 4% reservation in central government jobs for persons with benchmark disabilities
• Prohibition on discrimination in employment
• Reasonable accommodation obligation on employers

Assistive devices

ALIMCO (Artificial Limbs Manufacturing Corporation) provides wheelchairs, calipers, and other assistive devices at subsidised rates to UDID holders. Since 2024, ADIP applications go through the ARJUN portal (adip.depwd.gov.in) — district disability offices, NGOs, and camps still help with distribution. Scheme: ADIP (Assistance to Disabled Persons for Purchase/Fitting of Aids and Appliances).

Health coverage

Ayushman Bharat / Pradhan Mantri Jan Arogya Yojana (PMJAY) covers hospitalisation costs for eligible families. Check eligibility at pmjay.gov.in. Some state governments have additional disability welfare schemes — check your state disability welfare department.

Indian organisations

Key websites

• UDID / disability certificate: swavlambancard.gov.in
• Ayushman Bharat eligibility: pmjay.gov.in
• National Scholarship Portal: scholarships.gov.in
• ALIMCO (assistive devices): alimco.in
• Clinical trials in India: ctri.nic.in
• Parent Project MD (USA — treatment news): parentprojectmd.org

Diagnosis & genetics

Daily life

Treatment & prognosis

Practical & financial

Manual vs. power wheelchairs — when each becomes relevant

Most boys use a manual wheelchair or mobility scooter first, as a way to conserve energy for longer distances while some walking ability remains — not as a full-time replacement for walking. As arm strength declines and sitting for most of the day becomes the norm (this varies a great deal between boys and shouldn't be pinned to a fixed age), a manual chair stops being practical because self-propelling it strains already-weakened shoulder and arm muscles. International care recommendations advise moving to a power wheelchair sooner rather than later once walking becomes difficult, and power chairs with a stand-and-drive or power-standing feature are now often used in place of separate leg braces for supported standing. Custom seating — solid seat and back, hip guides, lateral trunk supports — should be built in from the start rather than retrofitted, which means involving a physiotherapist or wheelchair-seating clinic in the decision rather than buying off the shelf.

Common home modifications

Doorways need to be at least 34–36 inches wide for a wheelchair to pass through comfortably (offset hinges can recover an extra couple of inches without rebuilding the frame), and entrances work best with a zero-threshold or near-zero threshold rather than a raised sill. In the bathroom, grab bars must be screwed into plywood backing or wall studs — not towel rods, which aren't rated to take a person's weight — alongside a raised toilet seat and, where the budget allows, a roll-in shower rather than a high-lipped tub. A hospital-style adjustable bed makes a real difference for transfers as a boy gets heavier, since the caregiver can raise it to hip height instead of bending down each time; ramps generally follow a 1-inch rise per 1 foot of length with a non-slip surface. None of this needs to happen all at once — most families make these changes in stages as mobility changes, not as a single renovation.

Standing frames and prolonged standing

International care guidelines recommend starting a standing programme — using a standing frame or a wheelchair with an upright/standing feature — once a boy enters the early non-ambulatory stage, i.e. around the time walking is lost, provided contractures aren't already too severe to allow safe positioning. Regular weight-bearing helps slow bone density loss (relevant given steroid use), supports hip and knee joint alignment, and may help slow ankle/foot contractures. That said, the same guidelines note standing programmes should be used with caution once someone reaches the late non-ambulatory stage, since fixed contractures and fragile bones by then raise the risk of the device causing harm rather than benefit — set this up and adjust it with the physiotherapy team, not as a fixed daily quota.

Orthotics — AFOs and night splints

Ankle-foot orthoses (AFOs), commonly called night splints or "moon boots" by families, are usually introduced early — while a boy is still walking — and worn overnight to hold the ankle in a neutral position and provide a slow, sustained stretch that helps delay tightening of the calf and Achilles tendon. Starting them while a child is young makes tolerance easier to build up, before contractures set in. Daytime AFO use is generally avoided during the walking stage because it can increase fall risk and puts more demand on already-weak thigh muscles to compensate; once walking is lost, daytime AFOs are commonly reintroduced to help slow the specific pattern of ankle/foot contracture that develops from sitting. Fitting should be done by an orthotist or physiotherapist experienced with DMD, since off-the-shelf braces don't hold the ankle correctly for this condition.

How DMD can affect the brain, not just muscles

Dystrophin is not only a muscle protein — the DMD gene also produces brain-specific versions of the protein, expressed in areas involved in learning, memory and behaviour. Depending on where a boy's mutation falls on the gene, one or more of these brain-related forms may also be missing, not just the muscle form — which is why cognitive and behavioural profiles vary so much between boys and don't track cleanly with how weak the muscles are. This is the basis for a point families are rarely told plainly: attention, learning, or behavioural differences in a boy with DMD can be a direct effect of the missing protein on the brain itself, not a psychological reaction to being in a wheelchair or a result of parenting.

The 2018 international DMD care guideline reports substantially elevated rates of neurodevelopmental and psychiatric conditions compared with the general population: intellectual disability in 17–27%, learning disabilities in around 26%, autism spectrum traits in about 15%, ADHD in about 32%, and anxiety in about 27%. OCD and depression also occur at higher-than-typical rates, and ADHD frequently co-occurs with anxiety and learning disability in the same child, which can mask or complicate diagnosis if only one issue is investigated.

Parent and caregiver mental health

A large study of DMD caregivers (n=770) found that half reported moderate or extreme anxiety or depression — well above general-population rates — and that caregivers spending more than 50 hours a week on informal care had over three times the odds of anxiety or depression compared with those spending under 25 hours. Caregivers whose sons were in poorer perceived health had roughly six times the risk, and financial strain from care-related costs nearly doubled the odds. This is a documented, common outcome of the caregiving load — not a personal failing or a sign of coping badly.

The international care guideline states directly that a caregiver's own emotional adjustment should be monitored and support offered as needed, and recommends annual evaluation of the psychological wellbeing of the patient, parents, and siblings together — not the child in isolation. A stressed, exhausted, or emotionally overwhelmed caregiving environment measurably affects a child's own behavioural and emotional symptoms, which in turn increases parenting strain — meaning caregiver support isn't a luxury add-on but part of what keeps the child stable too. Build in respite where you can, stay connected to other adults outside the caregiving role, and treat asking for help as a normal part of managing a long-term condition, not a sign of coping badly.

Siblings

Siblings are named specifically in the international care guideline, which recommends they be given opportunities to connect with other siblings of children with DMD and access to mental health support as needed, and that their wellbeing be checked as part of the same annual family evaluation done for parents. Siblings often develop real strengths from the experience — increased maturity, tolerance for difference — but also carry mixed emotions (guilt, worry, feeling overlooked) that need to be acknowledged rather than dismissed. A recurring concern is siblings taking on caregiving responsibilities beyond what's appropriate for their age, at the cost of their own activities and peer life; a sibling who "seems fine" does not necessarily have no unmet needs.

Getting peer and family support in India

These Terms of Use govern your access to and use of Duchenne & Becker Muscular Dystrophy Saathi, a patient-education project of the Indian Federation of Neurorehabilitation (IFNR). By using this site, you agree to these terms.

1. Educational purpose only

All content on this site — including text, illustrations, checklists and any interactive tools — is provided for general educational and informational purposes only. It is not medical advice, and using this site does not create a doctor-patient relationship between you and IFNR, its members, or any contributor.

2. Not a substitute for professional care

Always seek the advice of a qualified physician or other healthcare provider for any questions about a diagnosis or treatment. Never delay or disregard professional medical advice because of something you have read here. If you believe you have a medical emergency, contact your local emergency services immediately.

3. Accuracy and no warranty

IFNR aims to keep this content accurate and current, and each page shows its review status. However, medical knowledge, government schemes and organisation details change over time, and we make no warranty — express or implied — that any information on this site is complete, current or error-free. Content is provided "as is."

4. Third-party organisations and links

This site may reference or link to government schemes, hospitals, NGOs and other third-party organisations. IFNR does not control these organisations and is not responsible for their content, services, availability or any outcome of contacting them. Inclusion of an organisation is not an endorsement.

5. Acceptable use

You agree not to misuse this site — for example, by attempting to disrupt it, scrape it at scale, misrepresent its content, or use it for any unlawful purpose.

6. Intellectual property

Unless stated otherwise, the content, design and branding of this site belong to IFNR. You may share and reference this content for personal, non-commercial, educational use with attribution; contact IFNR for any other use.

7. Limitation of liability

To the fullest extent permitted by law, IFNR and its contributors are not liable for any loss or damage arising from your use of, or reliance on, this site.

8. Governing law

These terms are governed by the laws of India.

9. Changes to these terms

IFNR may update these terms from time to time; the "last updated" date below reflects the most recent version.

Questions about these terms: ifnrsaathi@gmail.com

Last updated: 14 September 2026.